Gastric cancer
Conditions
Interventions
PDT+stent:NA
Stent:NA
Sponsors
Second Hospital of Lanzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Pathologically confirmed/or clinically confirmed advanced unresectable MGOO 2) Previously received or not received standard chemotherapy or targeted therapy or immunotherapy; 3) Age = 18 years old and no more than 75 years old; 4) Expected survival period = 3 months; 5) ECOG score 0-1; 6) There is at least one measurable tumor lesion: on spiral CT, the long diameter is = 10 mm, and the short diameter of lymph nodes is = 15 mm; in ordinary CT or physical examination, the maximum diameter must be = 20 mm; 7) No major organ failure 8) No severe coagulation dysfunction 9) Those who can tolerate electronic gastroscopy 10) Volunteer to join this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1) Those who are known to be allergic to photosensitizers and artificially synthesized monoclonal antibodies or immunosuppressants; 2) Patients who cannot tolerate local photodynamic surgery or electronic gastroscopy; 3) Patients who have previously received monoclonal antibody therapy and have irAEs of grade 2 or above; 4) Abdominal fistula, gastrointestinal perforation or abdominal abscess occurred within 6 months before the start of study treatment; 5) Suffering from any active autoimmune disease or history of autoimmune disease (such as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (hormone replacement After treatment can be included)); patients with complete remission of childhood asthma and no need for any intervention in adulthood or vitiligo can be included, but patients who require medical intervention with bronchodilators are not included; 6) Suffering from congenital or acquired immune deficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA = 500 IU/ml), hepatitis C (positive hepatitis C antibody, and high HCV-RNA lower limit of detection of the analytical method) or co-infection with hepatitis B and hepatitis C; 7) Patients with severe hepatic encephalopathy; 8) Obvious blood coagulation disorder, active bleeding and bleeding tendency; 9) There is a history of other malignant tumors within 5 years (adequately treated skin basal cell carcinoma, cervical in situ); 10) Patients with severe uncontrolled medical diseases, acute infections, recent history of myocardial infarction (within 3 months) and patients who cannot tolerate tumor treatment drugs; 11) Severe infection (such as: requiring intravenous infusion of antibiotics, antifungal or antiviral drugs) within 4 weeks before the first administration, or unexplained fever >38.5°C during the screening period/before the first administration; 12) During pregnancy or breastfeeding, and those who refuse to take appropriate contraceptive measures during this test; 13) The investigator believes that there is any condition that may harm the subject or cause the subject to be unable to meet or perform the research requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GOOSS;Overall survival;KPS;objective response rate;disease control rate;progression-free survival;duration of remission; | — |
Countries
China
Contacts
Public ContactHao Chen
Second Hospital of Lanzhou University
Outcome results
None listed